Abbott Aims For Mid-Year Products Reintroduction Following Consent Decree
This article was originally published in The Gray Sheet
Executive Summary
Abbott Laboratories hopes to reintroduce a number of its diagnostics products to the market in the second half of 2001 following a November 1999 consent decree issued by FDA.
You may also be interested in...
Abbott HIV P24 Antigen Test Recall Limited To About 350 Kits
A firm-initiated recall of Abbott's HIVAG-1 monoclonal HIV p24 antigen test kits initiated Feb. 13 stems from underfilled antibody vials and is limited to a single lot of about 350 test kits.
Abbott HIV P24 Antigen Test Recall Limited To About 350 Kits
A firm-initiated recall of Abbott's HIVAG-1 monoclonal HIV p24 antigen test kits initiated Feb. 13 stems from underfilled antibody vials and is limited to a single lot of about 350 test kits.
Abbott's AFP, CA 125 Cancer Tests Unaffected By Consent Decree
Abbott Laboratories' AFP and CA 125 diagnostic cancer tests are among the diagnostic products deemed "medically necessary" by FDA and will continue to be made available under the company's Nov. 2 consent decree with the agency.